Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
Cleveland Clinic Journal of Medicine. 2000 February;67(2):131-140
February 1, 2000|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACT
Glycoprotein (GP) Ilb/IIIa inhibitors are potent antiplatelet agents and represent an exciting breakthrough in the treatment of acute coronary syndromes. However, their safety and cost-effectiveness require further investigation, and more information on risk stratification is needed to clarify which patients benefit the most from empiric use of these agents.
